Children's Hospital celebrates European Commission approval of first-of-its-kind gene therapy for blindness

(Children's Hospital of Philadelphia) Children's Hospital of Philadelphia celebrates a pivotal moment in medicine: approval by the European Commission of LUXTURNA® (voretigene neparvovec), the first and only gene therapy for patients with an inherited retinal disease, last month. This also makes LUXTURNA the first gene therapy for a genetic disease that has received regulatory approval in both the US and European Union.

from EurekAlert! - Social and Behavioral Science https://ift.tt/2royU9Y